Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COPD pragmatic factorial cluster trial
ACTRN12620000649910Phase 4Completed
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide + formoterol in chronic obstructive pulmonary disease (COPD), asthma and nicotine dependence (4 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoints: Proportion with one or more acute exacerbations and Sustained validated smoking cessation. Started Jul 2020; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)asthmanicotine dependence
Beyond the preview
Go deeper on ACTRN12620000649910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000649910.